ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Galicia-Carmona, Tatiana; Arango-Bravo, Eder; Serrano-Olvera, Juan Alberto; Torre, Celia Flores-de la; Cruz-Esquivel, Iván; Valencia, Ricardo Villalobos; Morán-Mendoza, Andrés; Castro-Eguiluz, Denisse; Cetina, Lucely

doi:10.1080/21645515.2021.1893036

Cited by 15 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacterial vectors‐based vaccines : Listeria and Lactobacillus are the most widely studied vectors 308–310 . Listeria‐based vaccines ADXS11‐001 have undergone phase I/II clinical to assess their efficacy and safety in HPV+ cervical cancer (NCT02164461 and NCT01266460).…”

Section: Therapeutic Interventionsmentioning

confidence: 99%

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Ye,

Zheng,

et al. 2023

MedComm

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most prevalent sexually transmitted virus globally. Persistent high‐risk HPV infection can result in cervical precancerous lesions and cervical cancer, with 70% of cervical cancer cases associated with high‐risk types HPV16 and 18. HPV infection imposes a significant financial and psychological burden. Therefore, studying methods to eradicate HPV infection and halt the progression of precancerous lesions remains crucial. This review comprehensively explores the mechanisms underlying HPV‐related cervical lesions, including the viral life cycle, immune factors, epithelial cell malignant transformation, and host and environmental contributing factors. Additionally, we provide a comprehensive overview of treatment methods for HPV‐related cervical precancerous lesions and cervical cancer. Our focus is on immunotherapy, encompassing HPV therapeutic vaccines, immune checkpoint inhibitors, and advanced adoptive T cell therapy. Furthermore, we summarize the commonly employed drugs and other nonsurgical treatments currently utilized in clinical practice for managing HPV infection and associated cervical lesions. Gene editing technology is currently undergoing clinical research and, although not yet employed officially in clinical treatment of cervical lesions, numerous preclinical studies have substantiated its efficacy. Therefore, it holds promise as a precise treatment strategy for HPV‐related cervical lesions.

show abstract

Section: Therapeutic Interventionsmentioning

confidence: 99%

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Ye,

Zheng,

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Axalimogen filolisbac (ADXS11-001 or AXAL or ADXS-HPV) is an eLBP formulated by Advaxis which has become a well-known example in treating HPV-associated cancers. 87 ADXS11-001 is a type of immunotherapeutic drug that employs live attenuated L. monocytogenes -listeriolysin O (Lm-LLO) as its core component. It has been specifically engineered through biological means to produce an antigen-adjuvant fusion protein, which consists of an LLO truncated fragment fused to HPV.…”

Section: Geb and Cancer Therapymentioning

confidence: 99%

Genetically engineered bacteria: a new frontier in targeted drug delivery

Fooladi,

Rabiee,

Iravani

2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…These attenuated strains are commonly engineered to act as vaccines for specific forms of cancer, via secretion of a target antigen (Morrow et al, 2019). A prominent example is ADXS11-001 (also known as AXAL, or ADXS-HPV), an eLBP developed by Advaxis for the treatment of HPV-associated cancers (Galicia-Carmona et al, 2021). This prfA-defective strain secretes a truncated fragment of listeriolysin O (LLO), an immunological pore-forming protein, fused to HPV-16 E7 (Miles et al, 2017).…”

Section: Cancer Therapeuticsmentioning

confidence: 99%

Microbiome engineering: engineered live biotherapeutic products for treating human disease

Rutter

Dekker

Owen

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The human microbiota is implicated in many disease states, including neurological disorders, cancer, and inflammatory diseases. This potentially huge impact on human health has prompted the development of microbiome engineering methods, which attempt to adapt the composition and function of the human host-microbiota system for a therapeutic purpose. One promising method is the use of engineered microorganisms that have been modified to perform a therapeutic function. The majority of these products have only been demonstrated in laboratory models; however, in recent years more concepts have reached the translational stage. This has led to an increase in the number of clinical trials, which are designed to assess the safety and efficacy of these treatments in humans. Within this review, we highlight the progress of some of these microbiome engineering clinical studies, with a focus on engineered live biotherapeutic products.

show abstract

ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Cited by 15 publications

References 50 publications

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Genetically engineered bacteria: a new frontier in targeted drug delivery

Microbiome engineering: engineered live biotherapeutic products for treating human disease

Contact Info

Product

Resources

About